I am aligned with JBN on this. Whilst there is no certainty of course, it's highly unlikely there won't be a strong demand for the product given all the setbacks of current treatments and uniqueness of Spontan, and also because of what has been communicated by the company about being inundated with requests for the product. I don't see any reason at this time to not accept the veracity of that communication.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.040(2.94%) |
Mkt cap ! $111.9M | |||
| Open | High | Low | Value | Volume |
| $1.36 | $1.36 | $1.28 | $527.1K | 402.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 2042 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| LTP (ASX) Chart |